Surat Samachar

The Hereditary Angioedema Market in 7MM is expected to witness a major change in the study period 2019-2032

 Breaking News
  • No posts were found

The Hereditary Angioedema Market in 7MM is expected to witness a major change in the study period 2019-2032

November 21
10:24 2022
The Hereditary Angioedema Market in 7MM is expected to witness a major change in the study period 2019-2032

The Hereditary Angioedema Market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medicine development.

 

The Hereditary Angioedema market report provides current treatment practices, Hereditary Angioedema emerging drugs, and Hereditary Angioedema market share of the individual therapies, current and forecasted 7MM pancreatic cancer market size. The Hereditary Angioedema market research report also covers current Hereditary Angioedema treatment practice, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Key takeaways from the Hereditary Angioedema Market Research Report

  • An increase in Hereditary Angioedemamarket size is anticipated for the study period, 2019–2032.
  • The current understanding of HAE has greatly improved in recent decades, leading to growing awareness, improved management, and better outcomes.
  • Hereditary Angioedema Market Companies are working such as Takeda, Shire/Takeda, CSL Behring, Pharming Group, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, and others.
  • Hereditary Angioedema Pipeline Therapies such as Takhzyro, Firazyr, Cinryze, Kalbitor, Haegarda, Berinert, Ruconest, BCX7353, IONIS-PKK-LRx, KVD900, CSL312, and others.

 

Discover more about therapies set to grab major Hereditary Angioedema market research report @ Hereditary Angioedema Market Size

 

Hereditary Angioedema Overview

Hereditary angioedema (HAE) is a rare genetic disorder caused by a deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx. HAE is a heterogeneous disease with complex pathophysiology that involves several pathways resulting in the increased production of bradykinin with mutations of multiple molecules in genetic etiology. These could include the Kallikrein gene mutations; the bradykinin gene or its receptor mutations; Kininase 1 gene mutations, loss of function, and mutations in gene encoding amino peptidase and ACE enzymes.

 

Hereditary Angioedema Epidemiology Segmentation in the 7MM

  • Total Hereditary angioedema Diagnosed Prevalent Population
  • Hereditary angioedema Age-specific Cases
  • Hereditary angioedema Type-specific Cases
  • Hereditary angioedema Gender-specific Cases
  • Hereditary angioedema Site-specific Cases

 

Download the report to understand which factors are driving Hereditary Angioedema market trends @ Hereditary Angioedema Market Outlook

 

Hereditary Angioedema Treatment Market

Early targeted treatment of HAE attacks and preventative treatment for those with frequent attacks is the hallmark of the current management of HAE. The market overall has been segmented into two treatment strategies commonly used for HAE as on-demand therapies, which are taken to minimize the severity of angioedema symptoms and resolve symptoms as quickly as possible and further as long-term prophylaxis of attacks. Short-term (or periprocedural) prophylaxis treatment is taken before activities known to trigger attacks. Several options are available for treating acute attacks supported by robust data from clinical trials. Of the available acute treatment options, plasma-derived C1-INH, such as Berinert, and recombinant C1-INH (Ruconest) is administered intravenously. In contrast, icatibant (Firazyr) and ecallantide (Kalbitor) target the contact pathway and are administered subcutaneously.

 

Hereditary Angioedema Therapeutic Market

The market is expected to show positive growth, mainly attributed to the increased number of prevalent cases and the expected launch of therapies for acute treatment and prophylaxis during the forecast period (2019–2032). The therapies are novel, and their approval will tremendously affect the future. The landscape of therapeutic options for HAE patients will change dramatically in the next two decades due to the ongoing research that promises greater change in the foreseeable future. For instance, in October 2022, the FDA accepted for Priority Review the supplemental Biologics License Application (sBLA) for lanadelumab for prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients 2 to less than 12 years of age.

 

Learn more about the Hereditary Angioedema Market Forecast Report @ Hereditary Angioedema Market Share

 

Scope of the Hereditary Angioedema Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Forecast Period- 2022-2032
  • Hereditary Angioedema Companies- Takeda, Shire/Takeda, CSL Behring, Pharming Group, BioCryst Pharmaceuticals, Ionis Pharmaceuticals, KalVista Pharmaceuticals, and others
  • Hereditary Angioedema Therapies- Takhzyro, Firazyr, Cinryze, Kalbitor, Haegarda, Berinert, Ruconest, BCX7353, IONIS-PKK-LRx, KVD900, CSL312, and others.
  • Hereditary Angioedema Therapeutic Assessment: Hereditary Angioedema current marketed and emerging therapies
  • Hereditary Angioedema Market Dynamics:  Hereditary Angioedema market drivers and barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Hereditary Angioedema Market Access and Reimbursement

 

Table of Content

1. Key Insights

2. Hereditary Angioedema Executive Summary

3. Competitive Intelligence Analysis

4. Hereditary Angioedema: Market Overview at a Glance

5. Hereditary Angioedema: Disease Background and Overview

6. Hereditary Angioedema Patient Journey

7. Hereditary Angioedema Epidemiology and Patient Population

8. Hereditary Angioedema Treatment Algorithm, Current Treatment, and Medical Practices

9. Hereditary Angioedema Unmet Needs

10. Key Endpoints of Hereditary Angioedema Treatment

11. Hereditary Angioedema Marketed Products

12. Hereditary Angioedema Emerging Therapies

13. Hereditary Angioedema: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Hereditary Angioedema Market Outlook

16. Access and Reimbursement Overview of Hereditary Angioedema

17. KOL Views

18. Hereditary Angioedema Market Drivers

19. Hereditary Angioedema Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Do you have any queries? Connect to Business Consultant- Hereditary Angioedema Market Drivers and Barriers

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles